Video about Prothena alpha synuclein treatment

http://www.prothena.com/pipeline/prx...nsons-disease/

The biotech didn't disclose detailed efficacy results from the study but said PRX002 slashed mean alpha-synuclein by as much as 96% after a single dose, a free-of-context data point the company believes bodes well for its ongoing Phase I study on patients with Parkinson's.

http://www.fiercebiotech.com/story/r...rug/2015-03-19